Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents

被引:63
作者
Chatelut, E. [1 ]
White-Koning, M. L. [1 ]
Mathijssen, R. H. J. [2 ]
Puisset, F. [1 ]
Baker, S. D. [3 ]
Sparreboom, A. [3 ]
机构
[1] Univ Toulouse, EA Inst Claudius Regaud 4553, F-31052 Toulouse, France
[2] Erasmus Univ, Daniel den Hoed Canc Ctr, Med Ctr, Rotterdam, Netherlands
[3] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
关键词
dose banding; dose standardisation; anticancer drugs; fixed dose; chemotherapy; AFFECTING PHARMACOKINETIC VARIABILITY; CANCER-CHEMOTHERAPY; ANTICANCER DRUGS; IRINOTECAN; DOSAGE;
D O I
10.1038/bjc.2012.357
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Dose banding is a recently suggested dosing method that uses predefined ranges (bands) of body surface area (BSA) to calculate each patient's dose by using a single BSA-value per band. Thus, drugs with sufficient long-term stability can be prepared in advance. The main advantages of dose banding are to reduce patient waiting time and improve pharmacy capacity planning; additional benefits include reduced medication errors, reduced drug wastage, and prospective quality control. This study compares dose banding with individual BSA dosing and fixed dose according to pharmacokinetic criteria. METHODS: Three BSA bands were defined: BSA < 1.7 m(2), 1.7 m(2) <= BSA < 1.9 m(2), BSA >= 1.9 m(2) and each patient dose was calculated based on a unique BSA-value per band (1.55, 1.80, and 2.05 m(2), respectively). By using individual clearance values of six drugs (cisplatin, docetaxel, paclitaxel, doxorubicin, irinotecan, and topotecan) from 1012 adult cancer patients in total, the AUCs corresponding to three dosing methods (BSA dosing, dose banding, and fixed dose) were compared with a target AUC for each drug. RESULTS: For all six drugs, the per cent variation in individual dose obtained with dose banding compared with BSA dosing ranged between - 14% and + 22%, and distribution of AUC values was very similar with both dosing methods. In terms of reaching the target AUC, there was no significant difference in precision between dose banding and BSA dosing, except for paclitaxel (32.0% vs 30.7%, respectively; P < 0.05). However, precision was significantly better for BSA dosing compared with fixed dose for four out of six drugs. CONCLUSION: For the studied drugs, implementation of dose banding should be considered as it entails no significant increase in interindividual plasma exposure. British Journal of Cancer (2012) 107, 1100-1106. doi:10.1038/bjc.2012.357 www.bjcancer.com Published online 28 August 2012 (c) 2012 Cancer Research UK
引用
收藏
页码:1100 / 1106
页数:7
相关论文
共 17 条
  • [1] Effect of requiring advance approval of chemotherapy on number and cost of ungiven doses
    Berhoune, Malik
    Aboudagga, Hail
    Jacob, Aude
    Grandhaye, Jean-Pierre
    Dayot, Corinne
    Prognon, Patrice
    Bonan, Brigitte
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (07) : 557 - 558
  • [2] Flat-fixed dosing of irinotecan: Influence on pharmacokinetic and pharmacodynamic variability
    de Jong, FA
    Mathijssen, RHJ
    Xie, RJ
    Verweij, J
    Sparreboom, A
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (12) : 4068 - 4071
  • [3] Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure
    de Jongh, FE
    Verweij, J
    Loos, WJ
    de Wit, R
    de Jonge, MJA
    Planting, AST
    Nooter, K
    Stoter, G
    Sparreboom, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (17) : 3733 - 3739
  • [4] Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics - To test or not to test, that is the question
    Deeken, John F.
    Slack, Rebecca
    Marshall, John L.
    [J]. CANCER, 2008, 113 (07) : 1502 - 1510
  • [5] Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative
    Gurney, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (09) : 2590 - 2611
  • [6] Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel
    Henningsson, A
    Marsh, S
    Loos, WJ
    Karlsson, MO
    Garsa, A
    Mross, K
    Mielke, S
    Viganò, L
    Locatelli, A
    Verweij, J
    Sparreboom, A
    McLeod, HL
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (22) : 8097 - 8104
  • [7] Formula-based dosing for carboplatin
    Jodrell, DI
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 (09) : 1299 - 1301
  • [8] Factors affecting pharmacokinetic variability of oral topotecan:: a population analysis
    Léger, F
    Loos, WJ
    Fourcade, J
    Bugat, R
    Goffinet, M
    Mathijssen, RHJ
    Verweij, J
    Sparreboom, A
    Chatelut, E
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (02) : 343 - 347
  • [9] Mathijssen RHJ, 2001, CLIN CANCER RES, V7, P2182
  • [10] Flat-fixed dosing versus body surface area-based dosing of anticancer drugs in adults: Does it make a difference?
    Mathijssen, Ron H. J.
    De Jong, Floris A.
    Loos, Walter J.
    van der Bol, Jessica M.
    Verweij, Jaap
    Sparreboom, Alex
    [J]. ONCOLOGIST, 2007, 12 (08) : 913 - 923